JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT07336823
Phase
EARLY_PHASE1
Sponsor
Shenzhen Genocury Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • JY232 Injection
Locations (sample)
  • Foshan, Guangdong, China|23.02677,113.13148

Key Eligibility Criteria

  • The subject voluntarily signs the informed consent form, is willing and able to comply with all study requirements.
  • Age 18-75 years, male or female.
  • Diagnosis of active MM according to the diagnostic criteria established by the International Myeloma Working Group (IMWG).
  • Must have undergone stem cell transplantation (SCT) or be transplant-ineligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →